RxDoctor Payments Data

Olga Joukovski, MD

Internal Medicine · San Antonio, TXNPI 1437256179

Payments from drug & device makers

$5,444in general payments, 2019–2025

Across 152 payments — averaging $35.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$726
  • Lilly USA, LLC$356
  • Amgen$317
  • Dexcom, Inc.$292
  • plus $927 from 16 others

What the payments were for

  • Food & beverage$5,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,444 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$175,202
Medicare patients
305
Services billed
2,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin61$72,652
EliquisApixaban80$42,733
OzempicSemaglutide25$31,087
RybelsusSemaglutide14$29,292
TrulicityDulaglutide13$27,065
MyrbetriqMirabegron53$17,239
FarxigaDapagliflozin Propanediol11$10,532
TradjentaLinagliptin27$7,080
TrintellixVortioxetine Hydrobromide20$6,219
SymbicortBudesonide/Formoterol Fumarate16$4,152
Memantine Hcl78$2,963
Levothyroxine Sodium152$2,634
Gabapentin104$2,274
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$2,148
Duloxetine Hcl45$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$1,810$61,91552 claims
PfizerEliquis$155$42,73380 claims
Lilly USA, LLCTrulicity$356$27,06513 claims
AstraZenecaFarxiga, Symbicort$726$14,68327 claims
Boehringer IngelheimTradjenta$16$7,08027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →